Business Context and Reporting Period
Company: Prothena Corporation Public Limited Company
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2016
Event: Entry into a Material Definitive Agreement (Commercial Supply Contract).
Key Financial Metrics
This filing is a qualitative report regarding a contractual agreement and does not contain quantitative financial data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreement Details
On November 9, 2016, Prothena Therapeutics Limited entered into a Commercial Supply Contract with Rentschler Biotechnologie GmbH ("Rentschler"). Key terms include:
- Product: Bulk drug substance of NEOD001, a monoclonal antibody for the potential treatment of AL amyloidosis.
- Purpose: Worldwide commercial sale, contingent upon regulatory approval.
- Technology Transfer: Ongoing transfer of manufacturing technology from Boehringer Ingelheim Biopharmaceuticals GmbH to Rentschler.
- Term: Initial term of seven years with an automatic two-year extension unless terminated with 18 months' prior notice.
- Termination Rights: Prothena may terminate if technology transfer is not completed by June 30, 2017 (unless caused by Prothena). Either party may terminate for uncured material breach.
- Obligations: Prothena has a minimum purchase obligation but may source additional quantities from other manufacturers. Cancellation fees apply for binding orders unless Rentschler utilizes the reserved slots for other customers.
Guidance, Outlook, and Risks
Outlook: The agreement positions the company for potential commercial manufacturing of NEOD001 pending regulatory approval.
Risks and Contingencies:
- Commercial supply is conditional on receiving regulatory approval for NEOD001.
- Prothena faces a termination risk if the technology transfer from Boehringer Ingelheim to Rentschler is not completed by June 30, 2017.
- Financial exposure exists regarding cancellation fees for binding purchase orders.
Investor Verification Checklist
- Verify the status and timeline of the technology transfer from Boehringer Ingelheim to Rentschler.
- Monitor regulatory approval progress for NEOD001 for AL amyloidosis.
- Review the full Supply Contract (filed as an exhibit to the 2016 Form 10-K) for specific minimum purchase quantities and pricing terms, which are redacted in this summary.
- Assess the impact of potential cancellation fees on future cash flow if commercialization timelines shift.